Ayala Pharmaceuticals Inc (ADXS)

[hovacre]

Thus, 12-15 months will elapse from the time ADXS got FDA approval of the NEO IND in Mar 2017 (#msg-129238272) until the first patient in the phase-1 trial is dosed. Such a long delay can only mean one thing: ADXS does not yet have the NEO manufacturing squared away.

No, this is not true. Clinical trial sites can be difficult to secure, and they have to put in place all the protocols and recruitment procedures and other logistics before they can begin enrolling into this kind of trial, especially given the challenges associated with handling a bacterial vector-based therapy.